Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial

Olha Holubovska, Denisa Bojkova, Stefano Elli, Marco Bechtel, David Boltz, Miguel Muzzio, Xinjian Peng, Frederico Sala, Cesare Cosentino, Alla Mironenko, Jens Milde, Yuriy Lebed, Holger Stammer, Andrew Goy, Marco Guerrini, Lutz Mueller, Jindrich Cinatl, Victor Margitich, Aartjan J. W. te Velthuis
doi: https://doi.org/10.1101/2021.01.05.21249237
Back to top
Posted January 12, 2021.
Download PDF

Supplementary Material

Data/Code
Email
Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial
Olha Holubovska, Denisa Bojkova, Stefano Elli, Marco Bechtel, David Boltz, Miguel Muzzio, Xinjian Peng, Frederico Sala, Cesare Cosentino, Alla Mironenko, Jens Milde, Yuriy Lebed, Holger Stammer, Andrew Goy, Marco Guerrini, Lutz Mueller, Jindrich Cinatl, Victor Margitich, Aartjan J. W. te Velthuis
medRxiv 2021.01.05.21249237; doi: https://doi.org/10.1101/2021.01.05.21249237
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area